Travere Therapeutics (TVTX) said Thursday that Swissmedic offered temporary marketing approval for Filspari to treat adults with primary IgA nephropathy with a urine protein excretion of at least 1 gram per day.
The Swiss regulator's approval is supported by results from a phase 3 study and follows the US Food and Drug Administration's full marketing authorization along with conditional marketing approval by the European Medicines Agency, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.